华蟾素胶囊联合CAF方案治疗中晚期乳腺癌的临床效果分析(1)
摘要 目的：探讨华蟾素联合CAF方案治疗中晚期乳腺癌的临床疗效。方法：选取2015年2月至2017年2月三峡大学第三临床医学院葛洲坝集团中心医院收治的中晚期乳腺癌患者中筛选出41例，参照随机分配原则将其分为2组，联合组(20例)采用华蟾素联合CAF化疗治疗，CAF化疗组(21例)单纯给予CAF化疗治疗。治疗后3个月，评价和比较2组的近期和远期疗效、生命质量的改善情况、疼痛缓解率以及不良反应的发生情况。结果：治疗后3个月，联合组治疗有效率(75.00%)明显高于CAF化疗组(52.38%)(P<0.05)；联合组平均生存期为12个月，CAF化疗组为11个月，2组差异无统计学意义(P>0.05)。联合组的生命质量提高率(45.00%)明显高于CAF化疗组(23.81%)(P<0.05)。骨髓抑制、脱发和胃肠道反应为2组主要的不良反应，联合组胃肠道反应发生率(10.00%)明显低于CAF化疗组(23.81%)(P<0.05)，联合组脱发发生率(20.00%)也明显低于CAF化疗组(38.10%)(P<0.05)。治疗后联合组疼痛改善率(65.00%)优于CAF化疗组(52.81%)(P<0.05)。结论：华蟾素联合CAF化療方案治疗中晚期乳腺癌具有较好的近期效果，并能够缓解疼痛、改善患者的生命质量，且不良反应较少。
, 百拇医药
关键词 华蟾素；CAF方案；中晚期乳腺癌；临床效果分析
Abstract Objective：To investigate the clinical efficacy of cinobufotalin capsule combined CAF in the treatment of moderate and advanced breast cancer.Methods：A total of 41 patients with moderate and advanced breast cancer who were admitted and treated in our hospital from February 2015 to February 2017 were selected and randomly divided into the combined group (20 cases) and CAF chemotherapy group (21 cases).The combined group was treated with cinobufotalin combined with CAF，and the CAF chemotherapy group received chemotherapy only.After 3 months′ treatment，the short-term and long-term curative effects，quality of life，pain relief rate and adverse reactions were evaluated and compared between the two groups.Results：After 3 months′ treatment，the effective rate (75.00%) in combined group was significantly higher than 52.38% in CAF chemotherapy group (P<0.05).The mean survival time of the combined group was 12 months，and the CAF chemotherapy group was 11 months.The difference between two groups was not statistically significant (P>0.05).The improvement rate of life quality in the combined group (45.00%) was significantly higher than that in the CAF chemotherapy group (23.81%) (P<0.05).Myelosuppression，alopecia，and gastrointestinal reactions were the major adverse events in both groups and the incidence of gastrointestinal reaction in the combined group (10%) was significantly lower than that in the CAF chemotherapy group (23.81%) (P<0.05).The incidence of alopecia in the combined group (20.00%) was significantly lower than that in the CAF chemotherapy group (38.10%) (P<0.05).After treatment，the improvement rate of pain in the combined group (65.00%) was better than that in the CAF chemotherapy group (52.81%) (P<0.05).Conclusion：Cinobufotalin combined chemotherapy with CAF has better short-term therapeutic effect on moderate and advanced breast cancer，and can relieve pain and improve the quality of life of patients with few side effects., 百拇医药(柯红 崔洁 金锦莲 王磊)
, 百拇医药
关键词 华蟾素；CAF方案；中晚期乳腺癌；临床效果分析
Abstract Objective：To investigate the clinical efficacy of cinobufotalin capsule combined CAF in the treatment of moderate and advanced breast cancer.Methods：A total of 41 patients with moderate and advanced breast cancer who were admitted and treated in our hospital from February 2015 to February 2017 were selected and randomly divided into the combined group (20 cases) and CAF chemotherapy group (21 cases).The combined group was treated with cinobufotalin combined with CAF，and the CAF chemotherapy group received chemotherapy only.After 3 months′ treatment，the short-term and long-term curative effects，quality of life，pain relief rate and adverse reactions were evaluated and compared between the two groups.Results：After 3 months′ treatment，the effective rate (75.00%) in combined group was significantly higher than 52.38% in CAF chemotherapy group (P<0.05).The mean survival time of the combined group was 12 months，and the CAF chemotherapy group was 11 months.The difference between two groups was not statistically significant (P>0.05).The improvement rate of life quality in the combined group (45.00%) was significantly higher than that in the CAF chemotherapy group (23.81%) (P<0.05).Myelosuppression，alopecia，and gastrointestinal reactions were the major adverse events in both groups and the incidence of gastrointestinal reaction in the combined group (10%) was significantly lower than that in the CAF chemotherapy group (23.81%) (P<0.05).The incidence of alopecia in the combined group (20.00%) was significantly lower than that in the CAF chemotherapy group (38.10%) (P<0.05).After treatment，the improvement rate of pain in the combined group (65.00%) was better than that in the CAF chemotherapy group (52.81%) (P<0.05).Conclusion：Cinobufotalin combined chemotherapy with CAF has better short-term therapeutic effect on moderate and advanced breast cancer，and can relieve pain and improve the quality of life of patients with few side effects., 百拇医药(柯红 崔洁 金锦莲 王磊)